Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Chengdu Sdiya Biopharmaceutical received China's regulatory approval to start clinical trials for HRS-1635 tablets.
The approval is for the anti-tumor drug's clinical research in B-cell malignancies, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 2% in recent trade.
Shanghai Zhida Technology Development's (HKG:2650) shares will be added to the FTSE Global Equity Index Series following the latest quarterly review, according to a Tuesday Hong Kong bourse filing.Shares of the EV charging systems maker were up nearly 3% in Wednesday afternoon trade.The company said its shares will be included in the FTSE Global Equity Index Series Micro Cap and FTSE Total-Cap Index.The index changes will take effect after the market closes on June 19.
Changchun High-Tech Industry's (SHE:000661) subsidiary, Changchun GeneScience Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of GenSci144 tablets, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for phenylketonuria, a genetic disorder caused by defects in the phenylalanine hydroxylase gene, leading to hyperphenylalaninemia.The Chinese drug manufacturer's shares dropped 2% during the afternoon trade.
Haisco Pharmaceutical (SHE:002653) obtained approval from China's National Medical Products Administration for the clinical trials of the HSK44459 cream, according to a Wednesday filing on the Shenzhen bourse.The cream will be tested as a treatment for psoriasis and atopic dermatitis.